205 related articles for article (PubMed ID: 24589156)
21. A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma.
Amengual JE; Lichtenstein R; Lue J; Sawas A; Deng C; Lichtenstein E; Khan K; Atkins L; Rada A; Kim HA; Chiuzan C; Kalac M; Marchi E; Falchi L; Francescone MA; Schwartz L; Cremers S; O'Connor OA
Blood; 2018 Jan; 131(4):397-407. PubMed ID: 29141948
[TBL] [Abstract][Full Text] [Related]
22. Follicular mycosis fungoides: successful treatment with oral bexarotene.
Shistik G; Scalf LA; Fenske N; Glass LF
J Drugs Dermatol; 2004; 3(3):301-4. PubMed ID: 15176165
[TBL] [Abstract][Full Text] [Related]
23. Bexarotene and narrowband ultraviolet B phototherapy combination treatment for mycosis fungoides.
Lokitz ML; Wong HK
Photodermatol Photoimmunol Photomed; 2007 Dec; 23(6):255-7. PubMed ID: 17986063
[TBL] [Abstract][Full Text] [Related]
24. Pralatrexate for refractory mycosis fungoides in two Japanese patients.
Teraishi M; Oguro T; Kusume E; Kobashi H; Sano H; Fujioka A; Yamamoto M; Nakajima H; Sano S
J Dermatol; 2021 May; 48(5):667-671. PubMed ID: 33454985
[TBL] [Abstract][Full Text] [Related]
25. Pentostatin plus cyclophosphamide and bexarotene is an effective and safe combination in patients with mycosis fungoides/Sezary syndrome.
Calderon Cabrera C; de la Cruz Vicente F; Marín-Niebla A; Carrillo Cruz E; Rios Herranz E; Espigado Tocino I; Prats Martín C; Falantes JF; Martino Galiana ML; Perez-Simón JA
Br J Haematol; 2013 Jul; 162(1):130-2. PubMed ID: 23581433
[No Abstract] [Full Text] [Related]
26. Extracorporeal photopheresis in combination with bexarotene in the treatment of mycosis fungoides and Sézary syndrome.
Tsirigotis P; Pappa V; Papageorgiou S; Kapsimali V; Giannopoulou V; Kaitsa I; Girkas K; Papageorgiou E; Stavrianeas N; Economopoulos T; Dervenoulas J
Br J Dermatol; 2007 Jun; 156(6):1379-81. PubMed ID: 17459033
[No Abstract] [Full Text] [Related]
27. Role of radiation therapy in mycosis fungoides refractory to systemic therapy.
de Sanctis V; Persechino S; Fanelli A; Valeriani M; Bracci S; D'Arienzo M; Monarca B; Caperchi C; Raffa S; Enrici RM
Eur J Dermatol; 2011; 21(2):213-7. PubMed ID: 21489904
[TBL] [Abstract][Full Text] [Related]
28. Bexarotene in cutaneous T-cell lymphoma: third retrospective study of long-term cohort and review of the literature.
Quéreux G; Saint-Jean M; Peuvrel L; Brocard A; Knol AC; Dréno B
Expert Opin Pharmacother; 2013 Sep; 14(13):1711-21. PubMed ID: 23837676
[TBL] [Abstract][Full Text] [Related]
29. A phase 1 study of pralatrexate in combination with paclitaxel or docetaxel in patients with advanced solid tumors.
Azzoli CG; Krug LM; Gomez J; Miller VA; Kris MG; Ginsberg MS; Henry R; Jones J; Tyson L; Dunne M; Pizzo B; Farmer A; Venkatraman E; Steffen R; Sirotnak FM
Clin Cancer Res; 2007 May; 13(9):2692-8. PubMed ID: 17473201
[TBL] [Abstract][Full Text] [Related]
30. Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysis.
Hong JY; Yoon DH; Yoon SE; Kim SJ; Lee HS; Eom HS; Lee HW; Shin DY; Koh Y; Yoon SS; Jo JC; Kim JS; Kim SJ; Cho SH; Lee WS; Won JH; Kim WS; Suh C
Sci Rep; 2019 Dec; 9(1):20302. PubMed ID: 31889144
[TBL] [Abstract][Full Text] [Related]
31. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study.
O'Connor OA; Pro B; Pinter-Brown L; Bartlett N; Popplewell L; Coiffier B; Lechowicz MJ; Savage KJ; Shustov AR; Gisselbrecht C; Jacobsen E; Zinzani PL; Furman R; Goy A; Haioun C; Crump M; Zain JM; Hsi E; Boyd A; Horwitz S
J Clin Oncol; 2011 Mar; 29(9):1182-9. PubMed ID: 21245435
[TBL] [Abstract][Full Text] [Related]
32. A phase I trial of bexarotene in combination with docetaxel in patients with advanced solid tumors.
Malik SM; Collins B; Pishvaian M; Ramzi P; Marshall J; Hwang J
Clin Lung Cancer; 2011 Jul; 12(4):231-6. PubMed ID: 21726822
[TBL] [Abstract][Full Text] [Related]
33. Bexarotene treatment of late-stage mycosis fungoides and Sézary syndrome: development of extracutaneous lymphoma in 6 patients.
Bouwhuis SA; Davis MD; el-Azhary RA; McEvoy MT; Gibson LE; Knudsen JM; Kist JM; Pittelkow MR
J Am Acad Dermatol; 2005 Jun; 52(6):991-6. PubMed ID: 15928617
[TBL] [Abstract][Full Text] [Related]
34. [Treatment of mycosis fungoides with PUVA and bexarotene].
Ortiz-Romero PL; Sánchez-Largo ME; Sanz H; García-Romero D; Rosales B; Valverde R; Arrue I; Polo I; Ruiz D; Fernández-Herrera J; Vanaclocha F
Actas Dermosifiliogr; 2006 Jun; 97(5):311-8. PubMed ID: 16956562
[TBL] [Abstract][Full Text] [Related]
35. A phase I clinical pharmacologic study of pralatrexate in combination with probenecid in adults with advanced solid tumors.
Fury MG; Krug LM; Azzoli CG; Sharma S; Kemeny N; Wu N; Kris MG; Rizvi NA
Cancer Chemother Pharmacol; 2006 May; 57(5):671-7. PubMed ID: 16136310
[TBL] [Abstract][Full Text] [Related]
36. Juvenile mycosis fungoides treated with bexarotene and PUVA.
Rodríguez-Vázquez M; García-Arpa M; González-García J
Int J Dermatol; 2007 Jan; 46(1):99-102. PubMed ID: 17214731
[TBL] [Abstract][Full Text] [Related]
37. Phase I/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T-cell lymphoma.
Maruyama D; Nagai H; Maeda Y; Nakane T; Shimoyama T; Nakazato T; Sakai R; Ishikawa T; Izutsu K; Ueda R; Tobinai K
Cancer Sci; 2017 Oct; 108(10):2061-2068. PubMed ID: 28771889
[TBL] [Abstract][Full Text] [Related]
38. Alemtuzumab is an effective third-line treatment versus single-agent gemcitabine or pralatrexate for refractory Sézary syndrome: a systematic review.
Stewart JR; Desai N; Rizvi S; Zhu H; Goff HW
Eur J Dermatol; 2018 Dec; 28(6):764-774. PubMed ID: 30591425
[TBL] [Abstract][Full Text] [Related]
39. Oral bexarotene for post-transplant cutaneous T-cell lymphoma.
Lewis DJ; Huang S; Duvic M
Dermatol Ther; 2017 Sep; 30(5):. PubMed ID: 28748653
[TBL] [Abstract][Full Text] [Related]
40. The efficacy of vorinostat in combination with interferon alpha and extracorporeal photopheresis in late stage mycosis fungoides and Sezary syndrome.
Sanli H; Akay BN; Anadolu R; Ozcan M; Saral S; Akyol A
J Drugs Dermatol; 2011 Apr; 10(4):403-8. PubMed ID: 21455551
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
